Covers repurposing a heart-repair antibody approach to enhance kidney regeneration after injury and explores potential tissue and aging implications.
Key Takeaways
- Genetic ENPP1 loss or blockade enhanced kidney repair and reduced scarring in mice
- AD-NP1 is a monoclonal antibody engineered to specifically target human ENPP1
- AD-NP1 received FDA clearance to begin Phase 1 human clinical trials